Elevated Fractalkine in Patients with Obstructive Sleep Apnea Hypopnea Syndrome

Overview

Journal Sleep Breath

Publisher Springer

Date 2012 Mar 3

PMID 22382653

Citations 5

Authors

Yina Wang

Yayong Li

Ping Chen

Yingquan Luo

Yue Yang

Yu Yang

Affiliations

Soon will be listed here.

Abstract

Background: Obstructive sleep apnea hypopnea syndrome (OSAHS) has been increasingly linked to cardiovascular disease. Inflammatory processes associated with OSAHS may contribute to atherosclerosis in these patients. Fractalkine is a unique chemokine which has both adhesive and chemoattractant functions. We tested the hypothesis that OSAHS patients have increased fractalkine.

Methods And Results: We studied 20 patients (18 males and 2 females) with newly diagnosed OSAHS, who were free of other diseases, had never been treated for OSAHS, and were taking no medications. We compared fractalkine measurements in these patients to measurements obtained in 15 control subjects (14 males and 1 female) who were matched for age and body mass index, and in whom occult OSAHS was excluded. Plasma fractalkine levels were significantly higher in patients with OSAHS than in controls (463.15 ± 110.78 versus 364.67 ± 64.81 pg/mL, F = 2.58, P = 0.004). Fractalkine were associated with AHI (r = 0.756, P < 0.0001), lowest oxygen saturation (r = -0.466, P = 0.005), and mean oxygen saturation (r = -0.344, P = 0.043). Plasma fractalkine levels were significantly decreased in patients with OSAHS after four nights nCPAP (463.15 ± 110.78 versus 416.75 ± 97.67 pg/mL, P = 0.001).

Conclusions: OSAHS is associated with elevated levels of fractalkine, a marker of inflammation related to atherosclerosis. The severity of OSAHS is proportional to the fractalkine level.

Citing Articles

Fractalkine in obstructive sleep apnea patients.

Cetintas Afsar G, Oruc O, Sarac S, Bilgin Topcuoglu O, Salturk C, Tepetam F Sleep Breath. 2016; 21(2):355-359.

PMID: 27752937 DOI: 10.1007/s11325-016-1421-1.

Biomarkers associated with obstructive sleep apnea: A scoping review.

De Luca Canto G, Pacheco-Pereira C, Aydinoz S, Major P, Flores-Mir C, Gozal D Sleep Med Rev. 2015; 23:28-45.

PMID: 25645128 PMC: 4447611. DOI: 10.1016/j.smrv.2014.11.004.

Diagnostic capability of biological markers in assessment of obstructive sleep apnea: a systematic review and meta-analysis.

De Luca Canto G, Pacheco-Pereira C, Aydinoz S, Major P, Flores-Mir C, Gozal D J Clin Sleep Med. 2014; 11(1):27-36.

PMID: 25325575 PMC: 4265655. DOI: 10.5664/jcsm.4358.

Low serum copeptin levels in patients with obstructive sleep apnea.

Ozben S, Guvenc T, Huseyinoglu N, Sanivar H, Hanikoglu F, Cort A Sleep Breath. 2013; 17(4):1187-92.

PMID: 23407918 DOI: 10.1007/s11325-013-0822-7.

Emerging new biomarkers in obstructive sleep apnea.

Kapoor S Sleep Breath. 2012; 17(2):453.

PMID: 23114727 DOI: 10.1007/s11325-012-0778-z.

References

Chandrasekar B, Mummidi S, Perla R, Bysani S, Dulin N, Liu F . Fractalkine (CX3CL1) stimulated by nuclear factor kappaB (NF-kappaB)-dependent inflammatory signals induces aortic smooth muscle cell proliferation through an autocrine pathway. Biochem J. 2003; 373(Pt 2):547-58. PMC: 1223517. DOI: 10.1042/BJ20030207. View

Volin M, Huynh N, Klosowska K, Reyes R, Woods J . Fractalkine-induced endothelial cell migration requires MAP kinase signaling. Pathobiology. 2010; 77(1):7-16. PMC: 2840243. DOI: 10.1159/000272949. View

Nishimura M, Umehara H, Nakayama T, Yoneda O, Hieshima K, Kakizaki M . Dual functions of fractalkine/CX3C ligand 1 in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J Immunol. 2002; 168(12):6173-80. DOI: 10.4049/jimmunol.168.12.6173. View

Lin C, Davidson T, Ancoli-Israel S . Gender differences in obstructive sleep apnea and treatment implications. Sleep Med Rev. 2008; 12(6):481-96. PMC: 2642982. DOI: 10.1016/j.smrv.2007.11.003. View

Geissmann F, Jung S, Littman D . Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity. 2003; 19(1):71-82. DOI: 10.1016/s1074-7613(03)00174-2. View

White G, Tan T, John A, Whatling C, McPheat W, Greaves D . Fractalkine has anti-apoptotic and proliferative effects on human vascular smooth muscle cells via epidermal growth factor receptor signalling. Cardiovasc Res. 2009; 85(4):825-35. PMC: 2819832. DOI: 10.1093/cvr/cvp341. View

Liu H, Jiang D . Fractalkine/CX3CR1 and atherosclerosis. Clin Chim Acta. 2011; 412(13-14):1180-6. DOI: 10.1016/j.cca.2011.03.036. View

Garcia G, Xia Y, Chen S, Wang Y, Ye R, Harrison J . NF-kappaB-dependent fractalkine induction in rat aortic endothelial cells stimulated by IL-1beta, TNF-alpha, and LPS. J Leukoc Biol. 2000; 67(4):577-84. DOI: 10.1002/jlb.67.4.577. View

Vitale S, Schmid-Alliana A, Breuil V, Pomeranz M, Millet M, Rossi B . Soluble fractalkine prevents monocyte chemoattractant protein-1-induced monocyte migration via inhibition of stress-activated protein kinase 2/p38 and matrix metalloproteinase activities. J Immunol. 2003; 172(1):585-92. DOI: 10.4049/jimmunol.172.1.585. View

10.

Efsen E, Grappone C, Defranco R, Milani S, Romanelli R, Bonacchi A . Up-regulated expression of fractalkine and its receptor CX3CR1 during liver injury in humans. J Hepatol. 2002; 37(1):39-47. DOI: 10.1016/s0168-8278(02)00065-x. View

11.

Vgontzas A, Bixler E, Chrousos G . Sleep apnea is a manifestation of the metabolic syndrome. Sleep Med Rev. 2005; 9(3):211-24. DOI: 10.1016/j.smrv.2005.01.006. View

12.

Barlic J, Zhang Y, Foley J, Murphy P . Oxidized lipid-driven chemokine receptor switch, CCR2 to CX3CR1, mediates adhesion of human macrophages to coronary artery smooth muscle cells through a peroxisome proliferator-activated receptor gamma-dependent pathway. Circulation. 2006; 114(8):807-19. DOI: 10.1161/CIRCULATIONAHA.105.602359. View

13.

Drager L, Polotsky V, Lorenzi-Filho G . Obstructive sleep apnea: an emerging risk factor for atherosclerosis. Chest. 2011; 140(2):534-542. PMC: 3198492. DOI: 10.1378/chest.10-2223. View

14.

Bazan J, Bacon K, Hardiman G, Wang W, Soo K, Rossi D . A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997; 385(6617):640-4. DOI: 10.1038/385640a0. View

15.

Schulz C, Schafer A, Stolla M, Kerstan S, Lorenz M, von Bruhl M . Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin expressed on activated platelets. Circulation. 2007; 116(7):764-73. DOI: 10.1161/CIRCULATIONAHA.107.695189. View

16.

Volin M, Woods J, Amin M, Connors M, Harlow L, Koch A . Fractalkine: a novel angiogenic chemokine in rheumatoid arthritis. Am J Pathol. 2001; 159(4):1521-30. PMC: 1850492. DOI: 10.1016/S0002-9440(10)62537-0. View

17.

McDermott D, Fong A, Yang Q, Sechler J, Cupples L, Merrell M . Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest. 2003; 111(8):1241-50. PMC: 152935. DOI: 10.1172/JCI16790. View

18.

Moatti D, Faure S, Fumeron F, Seknadji P, McDermott D, Debre P . Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood. 2001; 97(7):1925-8. DOI: 10.1182/blood.v97.7.1925. View

19.

Mills P, Dimsdale J . Sleep apnea: a model for studying cytokines, sleep, and sleep disruption. Brain Behav Immun. 2004; 18(4):298-303. DOI: 10.1016/j.bbi.2003.10.004. View

20.

Yoneda O, Imai T, Goda S, Inoue H, Yamauchi A, Okazaki T . Fractalkine-mediated endothelial cell injury by NK cells. J Immunol. 2001; 164(8):4055-62. DOI: 10.4049/jimmunol.164.8.4055. View